Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival
Aim: This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and establish a prognostic nomogram to predict survival. Methods: One hundred seventeen patients with recurrent hepatocell...
Saved in:
Published in | Technology in cancer research & treatment Vol. 17; p. 1533033818801362 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Los Angeles, CA
SAGE Publications
01.01.2018
Sage Publications Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim:
This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and establish a prognostic nomogram to predict survival.
Methods:
One hundred seventeen patients with recurrent hepatocellular carcinoma receiving ablation from 2009 to 2014 were included in primary cohort to establish a prognostic nomogram. Between 2014 and 2016, 51 patients with recurrent hepatocellular carcinoma treated by ablation were enrolled in the validation cohort to validate the predictive accuracy of the nomogram. All patients underwent locoregional ablation. Overall survival was the primary end point, and progression-free survival was the second end point. The performance of the nomogram was assessed through concordance index and calibration curve and compared with 5 conventional hepatocellular carcinoma staging systems.
Results:
The 1-, 3-, and 5-year overall survival rates of primary cohort were 88.4%, 70.7%, and 64.1%, respectively. The 1-, 3-, and 5-year progression-free survival rates of primary cohort were 44%, 14%, and 8.7%, respectively. The results of multivariate analysis showed that tumor size (P = .0469; hazard ratio, 1.020; 95% confidence interval, 1.0004-1.040), preoperative extrahepatic disease (P = .0675; hazard ratio, 2.604; 95% confidence interval, 0.933-7.264), and close to hepatic hilum <2 cm (P = .0053; hazard ratio, 3.691; 95% confidence interval, 1.474-9.240) were predictive factors for overall survival. The study established a nomogram to predict survival (concordance index, 0.752; 95% confidence interval, 0.656-0.849). According to the predicted overall survival, patients with recurrent hepatocellular carcinoma were divided into 3 risk classes (P < .05): low-risk group (total score <55; predicted 5-year overall survival rate, 82.9%), intermediate-risk group (55 ≤ total score < 99; predicted 5-year overall survival rate, 52.8%), and high-risk group (hazard ratio, total score ≥99; predicted 5-year overall survival rate, not available).
Conclusion:
Percutaneous thermal ablation appears to be an effective procedure for the treatment of recurrent hepatocellular carcinoma after hepatectomy. The proposed nomogram provides a mechanism to accurately predict survival and could stratify risk among patients with recurrent hepatocellular carcinoma treated by ablation therapy. |
---|---|
AbstractList | Aim:This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and establish a prognostic nomogram to predict survival.Methods:One hundred seventeen patients with recurrent hepatocellular carcinoma receiving ablation from 2009 to 2014 were included in primary cohort to establish a prognostic nomogram. Between 2014 and 2016, 51 patients with recurrent hepatocellular carcinoma treated by ablation were enrolled in the validation cohort to validate the predictive accuracy of the nomogram. All patients underwent locoregional ablation. Overall survival was the primary end point, and progression-free survival was the second end point. The performance of the nomogram was assessed through concordance index and calibration curve and compared with 5 conventional hepatocellular carcinoma staging systems.Results:The 1-, 3-, and 5-year overall survival rates of primary cohort were 88.4%, 70.7%, and 64.1%, respectively. The 1-, 3-, and 5-year progression-free survival rates of primary cohort were 44%, 14%, and 8.7%, respectively. The results of multivariate analysis showed that tumor size (P = .0469; hazard ratio, 1.020; 95% confidence interval, 1.0004-1.040), preoperative extrahepatic disease (P = .0675; hazard ratio, 2.604; 95% confidence interval, 0.933-7.264), and close to hepatic hilum <2 cm (P = .0053; hazard ratio, 3.691; 95% confidence interval, 1.474-9.240) were predictive factors for overall survival. The study established a nomogram to predict survival (concordance index, 0.752; 95% confidence interval, 0.656-0.849). According to the predicted overall survival, patients with recurrent hepatocellular carcinoma were divided into 3 risk classes (P < .05): low-risk group (total score <55; predicted 5-year overall survival rate, 82.9%), intermediate-risk group (55 ≤ total score < 99; predicted 5-year overall survival rate, 52.8%), and high-risk group (hazard ratio, total score ≥99; predicted 5-year overall survival rate, not available).Conclusion:Percutaneous thermal ablation appears to be an effective procedure for the treatment of recurrent hepatocellular carcinoma after hepatectomy. The proposed nomogram provides a mechanism to accurately predict survival and could stratify risk among patients with recurrent hepatocellular carcinoma treated by ablation therapy. Aim: This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and establish a prognostic nomogram to predict survival. Methods: One hundred seventeen patients with recurrent hepatocellular carcinoma receiving ablation from 2009 to 2014 were included in primary cohort to establish a prognostic nomogram. Between 2014 and 2016, 51 patients with recurrent hepatocellular carcinoma treated by ablation were enrolled in the validation cohort to validate the predictive accuracy of the nomogram. All patients underwent locoregional ablation. Overall survival was the primary end point, and progression-free survival was the second end point. The performance of the nomogram was assessed through concordance index and calibration curve and compared with 5 conventional hepatocellular carcinoma staging systems. Results: The 1-, 3-, and 5-year overall survival rates of primary cohort were 88.4%, 70.7%, and 64.1%, respectively. The 1-, 3-, and 5-year progression-free survival rates of primary cohort were 44%, 14%, and 8.7%, respectively. The results of multivariate analysis showed that tumor size (P = .0469; hazard ratio, 1.020; 95% confidence interval, 1.0004-1.040), preoperative extrahepatic disease (P = .0675; hazard ratio, 2.604; 95% confidence interval, 0.933-7.264), and close to hepatic hilum <2 cm (P = .0053; hazard ratio, 3.691; 95% confidence interval, 1.474-9.240) were predictive factors for overall survival. The study established a nomogram to predict survival (concordance index, 0.752; 95% confidence interval, 0.656-0.849). According to the predicted overall survival, patients with recurrent hepatocellular carcinoma were divided into 3 risk classes (P < .05): low-risk group (total score <55; predicted 5-year overall survival rate, 82.9%), intermediate-risk group (55 ≤ total score < 99; predicted 5-year overall survival rate, 52.8%), and high-risk group (hazard ratio, total score ≥99; predicted 5-year overall survival rate, not available). Conclusion: Percutaneous thermal ablation appears to be an effective procedure for the treatment of recurrent hepatocellular carcinoma after hepatectomy. The proposed nomogram provides a mechanism to accurately predict survival and could stratify risk among patients with recurrent hepatocellular carcinoma treated by ablation therapy. This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and establish a prognostic nomogram to predict survival. One hundred seventeen patients with recurrent hepatocellular carcinoma receiving ablation from 2009 to 2014 were included in primary cohort to establish a prognostic nomogram. Between 2014 and 2016, 51 patients with recurrent hepatocellular carcinoma treated by ablation were enrolled in the validation cohort to validate the predictive accuracy of the nomogram. All patients underwent locoregional ablation. Overall survival was the primary end point, and progression-free survival was the second end point. The performance of the nomogram was assessed through concordance index and calibration curve and compared with 5 conventional hepatocellular carcinoma staging systems. The 1-, 3-, and 5-year overall survival rates of primary cohort were 88.4%, 70.7%, and 64.1%, respectively. The 1-, 3-, and 5-year progression-free survival rates of primary cohort were 44%, 14%, and 8.7%, respectively. The results of multivariate analysis showed that tumor size ( P = .0469; hazard ratio, 1.020; 95% confidence interval, 1.0004-1.040), preoperative extrahepatic disease ( P = .0675; hazard ratio, 2.604; 95% confidence interval, 0.933-7.264), and close to hepatic hilum <2 cm ( P = .0053; hazard ratio, 3.691; 95% confidence interval, 1.474-9.240) were predictive factors for overall survival. The study established a nomogram to predict survival (concordance index, 0.752; 95% confidence interval, 0.656-0.849). According to the predicted overall survival, patients with recurrent hepatocellular carcinoma were divided into 3 risk classes ( P < .05): low-risk group (total score <55; predicted 5-year overall survival rate, 82.9%), intermediate-risk group (55 ≤ total score < 99; predicted 5-year overall survival rate, 52.8%), and high-risk group (hazard ratio, total score ≥99; predicted 5-year overall survival rate, not available). Percutaneous thermal ablation appears to be an effective procedure for the treatment of recurrent hepatocellular carcinoma after hepatectomy. The proposed nomogram provides a mechanism to accurately predict survival and could stratify risk among patients with recurrent hepatocellular carcinoma treated by ablation therapy. AIMThis study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and establish a prognostic nomogram to predict survival.METHODSOne hundred seventeen patients with recurrent hepatocellular carcinoma receiving ablation from 2009 to 2014 were included in primary cohort to establish a prognostic nomogram. Between 2014 and 2016, 51 patients with recurrent hepatocellular carcinoma treated by ablation were enrolled in the validation cohort to validate the predictive accuracy of the nomogram. All patients underwent locoregional ablation. Overall survival was the primary end point, and progression-free survival was the second end point. The performance of the nomogram was assessed through concordance index and calibration curve and compared with 5 conventional hepatocellular carcinoma staging systems.RESULTSThe 1-, 3-, and 5-year overall survival rates of primary cohort were 88.4%, 70.7%, and 64.1%, respectively. The 1-, 3-, and 5-year progression-free survival rates of primary cohort were 44%, 14%, and 8.7%, respectively. The results of multivariate analysis showed that tumor size ( P = .0469; hazard ratio, 1.020; 95% confidence interval, 1.0004-1.040), preoperative extrahepatic disease ( P = .0675; hazard ratio, 2.604; 95% confidence interval, 0.933-7.264), and close to hepatic hilum <2 cm ( P = .0053; hazard ratio, 3.691; 95% confidence interval, 1.474-9.240) were predictive factors for overall survival. The study established a nomogram to predict survival (concordance index, 0.752; 95% confidence interval, 0.656-0.849). According to the predicted overall survival, patients with recurrent hepatocellular carcinoma were divided into 3 risk classes ( P < .05): low-risk group (total score <55; predicted 5-year overall survival rate, 82.9%), intermediate-risk group (55 ≤ total score < 99; predicted 5-year overall survival rate, 52.8%), and high-risk group (hazard ratio, total score ≥99; predicted 5-year overall survival rate, not available).CONCLUSIONPercutaneous thermal ablation appears to be an effective procedure for the treatment of recurrent hepatocellular carcinoma after hepatectomy. The proposed nomogram provides a mechanism to accurately predict survival and could stratify risk among patients with recurrent hepatocellular carcinoma treated by ablation therapy. |
Author | Wang, Yang Hu, Caixia Li, Wei Yuan, Zhuhui Gao, Wenfeng Zheng, Jiasheng |
AuthorAffiliation | Zhuhui Yuan, Yang Wang, and Caixia Hu contributed equally to this work 1 Center of Interventional Oncology and Liver Diseases, Beijing You’an Hospital, Capital Medical University, Beijing, China |
AuthorAffiliation_xml | – name: Zhuhui Yuan, Yang Wang, and Caixia Hu contributed equally to this work – name: 1 Center of Interventional Oncology and Liver Diseases, Beijing You’an Hospital, Capital Medical University, Beijing, China |
Author_xml | – sequence: 1 givenname: Zhuhui surname: Yuan fullname: Yuan, Zhuhui – sequence: 2 givenname: Yang surname: Wang fullname: Wang, Yang – sequence: 3 givenname: Caixia surname: Hu fullname: Hu, Caixia – sequence: 4 givenname: Wenfeng surname: Gao fullname: Gao, Wenfeng – sequence: 5 givenname: Jiasheng surname: Zheng fullname: Zheng, Jiasheng email: zhengjiasheng6@sina.com – sequence: 6 givenname: Wei orcidid: 0000-0003-3660-1492 surname: Li fullname: Li, Wei |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30244651$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk2P0zAQhiO0iP2AOydkiQuXQBw7TnpBqqrCIq1gBUUco7Ezbr1K7GI7lco_49_hKEuBlTjZmnnmtWfmvczOrLOYZc9p8ZrSun5DK8YKxhraNAVlonyUXUyhfIqdne5cnGeXIdwVRSkEo0-yc1aUnIuKXmQ_11obBepInCa36NUYwaIbA9ns0A_Qk6XsIRpnycoN0ljsyDcTd2TjwQbwEb1J0HqQrjc_ZlA7Tz6jGr1HG8k17iE6hX0_9uDJCrwy1g1AljoVz2lU0Q1HArYjQG6921oXolHkoxvc1sNAokth7IyK5MvoD-YA_dPssYY-4LP78yr7-m69WV3nN5_ef1gtb3LFRRlz0dEF7ZBXDBh2KAWqrpG0aLCWvJIcaooNygXVFBnnWldcVnXFZA2irErBrrK3s-5-lAN2KvXkoW_33gzgj60D0_6bsWbXbt2hFWn8FaNJ4NW9gHffRwyxHUyY5jEPui1p2mXahmgS-vIBeudGb1N7bZmUFnUjyokqZkp5F4JHffoMLdrJF-1DX6SSF383cSr4bYQE5DMQYIt_Xv2v4C8C5caZ |
CitedBy_id | crossref_primary_10_1155_2020_8872329 crossref_primary_10_1002_cam4_3250 crossref_primary_10_1002_cam4_5880 crossref_primary_10_1080_02656736_2022_2059581 crossref_primary_10_1007_s00261_020_02426_5 crossref_primary_10_3389_fonc_2022_939358 crossref_primary_10_1007_s00270_020_02617_z |
Cites_doi | 10.1148/radiology.214.3.r00mr02761 10.1002/cncr.21832 10.1016/j.jvir.2016.06.010 10.1002/cncr.10384 10.1097/00000658-199902000-00009 10.1053/jhep.2001.23561 10.18632/oncotarget.8331 10.1097/01.sla.0000094549.11754.e6 10.1148/radiol.14141568 10.1002/hep.510300629 10.18632/oncotarget.11514 10.1002/cncr.30008 10.1016/j.surg.2014.10.019 10.1016/S0140-6736(11)61347-0 10.21873/anticanres.11211 10.1055/s-0030-1247133 10.1245/s10434-006-9220-8 10.1148/radiol.2343040350 10.1002/lt.21078 10.1002/hep.24199 10.1097/MEG.0000000000000383 10.1097/MEG.0b013e32834c5b13 10.1007/s00270-013-0708-x 10.1053/j.gastro.2008.02.091 10.1245/s10434-016-5136-0 10.1002/cncr.21043 10.1007/s00432-016-2286-1 10.1002/hep.510280322 10.1016/j.jhep.2015.02.034 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E 10.1016/S1470-2045(17)30683-6 10.1002/1097-0142(19921101)70:9<2263::AID-CNCR2820700909>3.0.CO;2-M 10.1148/radiol.2281020718 10.1007/s12013-014-9840-8 10.1097/01.RVI.0000094601.83406.e1 10.1097/MD.0000000000002252 10.1055/s-2007-1007122 10.1002/cncr.20892 10.1001/jamasurg.2015.4257 10.1007/PL00009947 10.1016/j.jvir.2009.11.006 10.1016/j.surg.2005.02.008 10.1097/COC.0b013e3181967da0 10.1097/TP.0b013e3182a89383 10.1002/hep.510250116 10.1016/j.crad.2014.01.015 10.1056/NEJMra1001683 10.3109/02656736.2011.605099 10.1097/01.RVI.0000182185.47500.7A 10.1097/SLA.0000000000000882 10.1111/hpb.12324 10.1016/j.ejso.2014.11.002 10.1007/s12328-015-0599-2 10.1159/000367755 |
ContentType | Journal Article |
Copyright | The Author(s) 2018 The Author(s) 2018. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2018 2018 SAGE Publications |
Copyright_xml | – notice: The Author(s) 2018 – notice: The Author(s) 2018. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2018 2018 SAGE Publications |
DBID | AFRWT NPM AAYXX CITATION 3V. 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1177/1533033818801362 |
DatabaseName | SAGE Open Access PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Access via ProQuest (Open Access) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: AFRWT name: SAGE Open Access url: http://journals.sagepub.com/ sourceTypes: Publisher – sequence: 3 dbid: 7X7 name: ProQuest - Health & Medical Complete保健、医学与药学数据库 url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1533-0338 |
EndPage | 1533033818801362 |
ExternalDocumentID | 10_1177_1533033818801362 30244651 10.1177_1533033818801362 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: National Major Scientific Instruments and Equipment Development Project grantid: ZDYZ2015-2 – fundername: ; grantid: ZDYZ2015-2 |
GroupedDBID | --- 0R~ 123 53G 54M 7X7 8FI 8FJ AAJPV AAJQC AARDL AARIX AATBZ ABAWP ABQXT ABRHV ABUWG ABVFX ACARO ACDXX ACGFS ACGZU ACROE ACSIQ ACUIR ADBBV ADOGD ADPDF AENEX AERKM AEUHG AEUIJ AEWDL AEWHI AFCOW AFKRA AFKRG AFRWT AFUIA AGNHF AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ARTOV AUTPY AYAKG BDDNI BENPR BKSCU BPHCQ BSEHC BVXVI CCPQU DC. DV7 EBS EJD F5P FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HMCUK HYE J8X JCYGO K.F M4V O9- OK1 OVD OVEED P2P PIMPY PQQKQ ROL RPM SFC SJN TEORI UKHRP Y4B ZONMY ZPPRI ZRKOI ZSSAH NPM AAYXX CITATION 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c462t-6d191de453a3edeb6ecd8b108e7b45b4a71e8eb91f1e344ff54b5753b7a625263 |
IEDL.DBID | RPM |
ISSN | 1533-0346 |
IngestDate | Tue Sep 17 21:14:41 EDT 2024 Sat Oct 05 05:34:01 EDT 2024 Fri Sep 13 02:00:20 EDT 2024 Wed Oct 02 14:44:25 EDT 2024 Sat Sep 28 08:36:34 EDT 2024 Sun Sep 15 05:40:23 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | recurrent hepatocellular carcinoma hepatectomy percutaneous thermal ablation HCC nomogram |
Language | English |
License | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c462t-6d191de453a3edeb6ecd8b108e7b45b4a71e8eb91f1e344ff54b5753b7a625263 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-3660-1492 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153531/ |
PMID | 30244651 |
PQID | 2313978628 |
PQPubID | 4450582 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6153531 proquest_miscellaneous_2111746568 proquest_journals_2313978628 crossref_primary_10_1177_1533033818801362 pubmed_primary_30244651 sage_journals_10_1177_1533033818801362 |
PublicationCentury | 2000 |
PublicationDate | 2018-01-01 |
PublicationDateYYYYMMDD | 2018-01-01 |
PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Los Angeles, CA |
PublicationPlace_xml | – name: Los Angeles, CA – name: United States – name: Thousand Oaks – name: Sage CA: Los Angeles, CA |
PublicationTitle | Technology in cancer research & treatment |
PublicationTitleAlternate | Technol Cancer Res Treat |
PublicationYear | 2018 |
Publisher | SAGE Publications Sage Publications Ltd |
Publisher_xml | – name: SAGE Publications – name: Sage Publications Ltd |
References | Forner, Reig, de Lope, Bruix 2010; 30 Zou, Li, Wu 2016; 23 Lee, Lee, Lee, Kim, Han, Choi 2014; 37 Llovet, Bru, Bruix 1999; 19 Giorgio, Merola, Montesarchio 2016; 36 Georgiades, Hong, D’Angelo, Geschwind 2005; 16 Yamanaka, Okamoto, Fujihara 1992; 70 Poon, Fan, Lo, Liu, Wong 1999; 229 Chen, Gan, Ge 2016; 27 Vilgrain, Pereira, Assenat 2017; 18 Takeda, Sanuki, Tsurugai 2016; 122 Forner, Llovet, Bruix 2012; 379 Lencioni, Allgaier, Cioni 2003; 228 Lin, Cheng, Chen, Lin 2016; 5 Yamashita, Aoki, Inoue 2015; 157 Zhou, Shan, Zhu 2010; 21 Omary, Bettmann, Cardella 2003; 14 Jonas, Bechstein, Steinmuller 2001; 33 Livraghi, Goldberg, Lazzaroni 2000; 214 1998; 28 Yang, Fu, Lau 2012; 59 Wu, Hou, Ding 2015; 94 Wan, Zhai, Yan 2016; 7 Okuda, Ohtsuki, Obata 1985; 56 Tateishi, Shiina, Teratani 2005; 103 Mise, Hasegawa, Shindoh 2015; 262 Xu, Peng, Chen 2015; 63 Lei, Li, Wu 2016; 151 Zheng, Liang, Milgrom 2014; 97 Lencioni, Cioni, Crocetti 2005; 234 Imai, Hirooka, Ochi 2015; 8 Jiang, Zhang, Liu 2014; 69 Choi, Park, Ahn 2009; 32 Choi, Lim, Rhim 2007; 14 Zheng, Long, Sun 2014; 69 Bruix, Sherman 2011; 53 Liu, Liang, Liu 2011; 27 Lin, Chiou, Chou 2011; 23 El-Serag 2011; 365 Yamagami, Yoshimatsu, Ishikawa 2014; 61 Kim, Park, Lim 2005; 103 Kumada, Nakano, Takeda 1997; 25 Li, Liu, Li 2016; 7 Leung, Tang, Zee 2002; 94 Feng, Dong, Lau 2017; 143 Obi, Yoshida, Toune 2006; 106 Castroagudin, Gonzalez-Quintela, Martinez, Tome, Forteza, Varo 2002; 49 Regalia, Fassati, Valente 1998; 5 Dai, Cheung, Chok 2015; 17 Parfitt, Marotta, Alghamdi 2007; 13 Zhang, Shen, Zhao, Guan, Chen, Li 2018; 24 Llovet, Fuster, Bruix 1999; 30 Song, Lim, Rhim 2015; 275 Zhang, Li, Wen 2015; 27 Ishizawa, Hasegawa, Aoki 2008; 134 Makino, Chijiiwa, Kondo, Ohuchida, Kai 2005; 137 Minagawa, Makuuchi, Takayama, Kokudo 2003; 238 Wang, Liu, Li 2015; 41 bibr53-1533033818801362 bibr45-1533033818801362 bibr10-1533033818801362 bibr28-1533033818801362 bibr6-1533033818801362 bibr11-1533033818801362 bibr37-1533033818801362 bibr38-1533033818801362 bibr46-1533033818801362 bibr52-1533033818801362 bibr8-1533033818801362 bibr29-1533033818801362 bibr55-1533033818801362 bibr43-1533033818801362 bibr47-1533033818801362 bibr51-1533033818801362 bibr26-1533033818801362 bibr39-1533033818801362 bibr13-1533033818801362 bibr18-1533033818801362 bibr20-1533033818801362 bibr44-1533033818801362 bibr5-1533033818801362 bibr54-1533033818801362 bibr57-1533033818801362 bibr41-1533033818801362 bibr36-1533033818801362 bibr23-1533033818801362 bibr40-1533033818801362 bibr58-1533033818801362 Yang Y (bibr49-1533033818801362) 2012; 59 bibr15-1533033818801362 bibr31-1533033818801362 bibr24-1533033818801362 bibr2-1533033818801362 bibr33-1533033818801362 bibr3-1533033818801362 bibr25-1533033818801362 bibr59-1533033818801362 bibr16-1533033818801362 bibr17-1533033818801362 bibr30-1533033818801362 bibr34-1533033818801362 bibr9-1533033818801362 Zhang R (bibr21-1533033818801362) 2018; 24 bibr4-1533033818801362 bibr42-1533033818801362 bibr56-1533033818801362 Yamagami T (bibr12-1533033818801362) 2014; 61 bibr48-1533033818801362 bibr50-1533033818801362 bibr22-1533033818801362 bibr35-1533033818801362 bibr14-1533033818801362 bibr19-1533033818801362 bibr27-1533033818801362 bibr1-1533033818801362 Castroagudin JF (bibr7-1533033818801362) 2002; 49 bibr32-1533033818801362 |
References_xml | – volume: 32 start-page: 564 issue: 6 year: 2009 end-page: 569 article-title: Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection publication-title: Am J Clin Oncol contributor: fullname: Ahn – volume: 7 start-page: 83806 issue: 50 year: 2016 end-page: 83816 article-title: Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma publication-title: Oncotarget contributor: fullname: Yan – volume: 275 start-page: 599 issue: 2 year: 2015 end-page: 608 article-title: Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study publication-title: Radiology contributor: fullname: Rhim – volume: 27 start-page: 933 issue: 8 year: 2015 end-page: 940 article-title: Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern publication-title: Eur J Gastroenterol Hepatol contributor: fullname: Wen – volume: 19 start-page: 329 issue: 3 year: 1999 end-page: 338 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification publication-title: Semin Liver Dis contributor: fullname: Bruix – volume: 63 start-page: 122 issue: 1 year: 2015 end-page: 130 article-title: Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization publication-title: J Hepatol contributor: fullname: Chen – volume: 23 start-page: 2618 issue: 8 year: 2016 end-page: 2626 article-title: Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma publication-title: Ann Surg Oncol contributor: fullname: Wu – volume: 37 start-page: 705 issue: 3 year: 2014 end-page: 715 article-title: Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis publication-title: Cardiovasc Intervent Radiol contributor: fullname: Choi – volume: 151 start-page: 356 issue: 4 year: 2016 end-page: 363 article-title: Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria publication-title: JAMA Surg contributor: fullname: Wu – volume: 27 start-page: 654 issue: 7 year: 2011 end-page: 662 article-title: MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma publication-title: Int J Hyperthermia contributor: fullname: Liu – volume: 28 start-page: 751 issue: 3 year: 1998 end-page: 755 article-title: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators publication-title: Hepatology – volume: 49 start-page: 249 issue: 43 year: 2002 end-page: 251 article-title: Bilateral adrenal metastases from hepatocellular carcinoma after liver transplantation publication-title: Hepatogastroenterology contributor: fullname: Varo – volume: 228 start-page: 235 issue: 1 year: 2003 end-page: 240 article-title: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection publication-title: Radiology contributor: fullname: Cioni – volume: 25 start-page: 87 issue: 1 year: 1997 end-page: 92 article-title: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma publication-title: Hepatology contributor: fullname: Takeda – volume: 16 start-page: 1653 issue: 12 year: 2005 end-page: 1659 article-title: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis publication-title: J Vasc Interv Radiol contributor: fullname: Geschwind – volume: 30 start-page: 1434 issue: 6 year: 1999 end-page: 1440 article-title: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation publication-title: Hepatology contributor: fullname: Bruix – volume: 97 start-page: 227 issue: 2 year: 2014 end-page: 234 article-title: Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies publication-title: Transplantation contributor: fullname: Milgrom – volume: 61 start-page: 1387 issue: 133 year: 2014 end-page: 1392 article-title: Transcatheter arterial chemoembolization with an interventional-CT system for recurrent hepatocellular carcinoma after living donor liver transplantation publication-title: Hepatogastroenterology contributor: fullname: Ishikawa – volume: 56 start-page: 918 issue: 4 year: 1985 end-page: 928 article-title: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients publication-title: Cancer contributor: fullname: Obata – volume: 69 start-page: e253 issue: 6 year: 2014 end-page: e263 article-title: Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation? publication-title: Clin Radiol contributor: fullname: Sun – volume: 21 start-page: 333 issue: 3 year: 2010 end-page: 338 article-title: Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation publication-title: J Vasc Interv Radiol contributor: fullname: Zhu – volume: 94 start-page: 1760 issue: 6 year: 2002 end-page: 1769 article-title: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients publication-title: Cancer contributor: fullname: Zee – volume: 214 start-page: 761 issue: 3 year: 2000 end-page: 768 article-title: Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions publication-title: Radiology contributor: fullname: Lazzaroni – volume: 7 start-page: 24623 issue: 17 year: 2016 end-page: 24632 article-title: Proper hepatic pedicle clamping during hepatectomy is associated with improved postoperative long-term prognosis in patients with AJCC stage IIIB hepatocellular carcinoma publication-title: Oncotarget contributor: fullname: Li – volume: 103 start-page: 2419 issue: 11 year: 2005 end-page: 2426 article-title: Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma publication-title: Cancer contributor: fullname: Lim – volume: 13 start-page: 543 issue: 4 year: 2007 end-page: 551 article-title: Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence publication-title: Liver Transpl contributor: fullname: Alghamdi – volume: 69 start-page: 605 issue: 3 year: 2014 end-page: 617 article-title: “One-off” complete radiofrequency ablation for hepatocellular carcinoma in a “high-risk location” adjacent to the major bile duct and hepatic blood vessel publication-title: Cell Biochem Biophys contributor: fullname: Liu – volume: 24 start-page: 219 issue: 4 year: 2018 end-page: 224 article-title: Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma publication-title: Diagn Interv Radiol contributor: fullname: Li – volume: 229 start-page: 216 issue: 2 year: 1999 end-page: 222 article-title: Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors publication-title: Ann Surg contributor: fullname: Wong – volume: 8 start-page: 318 issue: 5 year: 2015 end-page: 322 article-title: A case of hepatocellular carcinoma treated by radiofrequency ablation confirming the adjacent major bile duct under hybrid contrast mode through a biliary drainage catheter publication-title: Clin J Gastroenterol contributor: fullname: Ochi – volume: 17 start-page: 226 issue: 3 year: 2015 end-page: 231 article-title: Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm publication-title: HPB (Oxford) contributor: fullname: Chok – volume: 59 start-page: 1560 issue: 117 year: 2012 end-page: 1565 article-title: Selective main portal vein clamping to minimize the risk of recurrence after curative liver resection for hepatocellular carcinoma publication-title: Hepatogastroenterology contributor: fullname: Lau – volume: 94 start-page: e2252 issue: 49 year: 2015 article-title: Cryoablation versus radiofrequency ablation for hepatic malignancies: a systematic review and literature-based analysis publication-title: Medicine (Baltimore) contributor: fullname: Ding – volume: 70 start-page: 2263 issue: 9 year: 1992 end-page: 2267 article-title: Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection? publication-title: Cancer contributor: fullname: Fujihara – volume: 365 start-page: 1118 issue: 12 year: 2011 end-page: 1127 article-title: Hepatocellular carcinoma publication-title: N Engl J Med contributor: fullname: El-Serag – volume: 234 start-page: 961 issue: 3 year: 2005 end-page: 967 article-title: Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation publication-title: Radiology contributor: fullname: Crocetti – volume: 238 start-page: 703 issue: 5 year: 2003 end-page: 710 article-title: Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma publication-title: Ann Surg contributor: fullname: Kokudo – volume: 262 start-page: 347 issue: 2 year: 2015 end-page: 357 article-title: The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma publication-title: Ann Surg contributor: fullname: Shindoh – volume: 36 start-page: 6179 issue: 11 year: 2016 end-page: 6183 article-title: Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a Western randomized controlled trial publication-title: Anticancer Res contributor: fullname: Montesarchio – volume: 103 start-page: 1201 issue: 6 year: 2005 end-page: 1209 article-title: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases publication-title: Cancer contributor: fullname: Teratani – volume: 14 start-page: 2319 issue: 8 year: 2007 end-page: 2329 article-title: Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors publication-title: Ann Surg Oncol contributor: fullname: Rhim – volume: 33 start-page: 1080 issue: 5 year: 2001 end-page: 1086 article-title: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis publication-title: Hepatology contributor: fullname: Steinmuller – volume: 53 start-page: 1020 issue: 3 year: 2011 end-page: 1022 article-title: American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update publication-title: Hepatology contributor: fullname: Sherman – volume: 137 start-page: 626 issue: 6 year: 2005 end-page: 631 article-title: Prognostic benefit of selective portal vein occlusion during hepatic resection for hepatocellular carcinoma publication-title: Surgery contributor: fullname: Kai – volume: 30 start-page: 61 issue: 1 year: 2010 end-page: 74 article-title: Current strategy for staging and treatment: the BCLC update and future prospects publication-title: Semin Liver Dis contributor: fullname: Bruix – volume: 106 start-page: 1990 issue: 9 year: 2006 end-page: 1997 article-title: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion publication-title: Cancer contributor: fullname: Toune – volume: 27 start-page: 1829 issue: 12 year: 2016 end-page: 1836 article-title: Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within Barcelona Clinic Liver Cancer stage 0/A: a retrospective comparative study publication-title: J Vasc Interv Radiol contributor: fullname: Ge – volume: 14 start-page: S293 issue: 9 pt 2 year: 2003 end-page: S295 article-title: Quality improvement guidelines for the reporting and archiving of interventional radiology procedures publication-title: J Vasc Interv Radiol contributor: fullname: Cardella – volume: 5 start-page: 8 issue: 1 year: 2016 end-page: 20 article-title: The effectiveness of multiple electrode radiofrequency ablation in patients with hepatocellular carcinoma with lesions more than 3 cm in size and Barcelona Clinic Liver Cancer stage A to B2 publication-title: Liver Cancer contributor: fullname: Lin – volume: 122 start-page: 2041 issue: 13 year: 2016 end-page: 2049 article-title: Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation publication-title: Cancer contributor: fullname: Tsurugai – volume: 143 start-page: 293 issue: 2 year: 2017 end-page: 303 article-title: Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma publication-title: J Cancer Res Clin Oncol contributor: fullname: Lau – volume: 41 start-page: 236 issue: 2 year: 2015 end-page: 242 article-title: Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study publication-title: Eur J Surg Oncol contributor: fullname: Li – volume: 18 start-page: 1624 issue: 12 year: 2017 end-page: 1636 article-title: Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial publication-title: Lancet Oncol contributor: fullname: Assenat – volume: 23 start-page: 1239 issue: 12 year: 2011 end-page: 1244 article-title: Radiofrequency ablation for recurrent hepatocellular carcinoma in postresectional patients: prognostic factors analysis publication-title: Eur J Gastroenterol Hepatol contributor: fullname: Chou – volume: 379 start-page: 1245 issue: 9822 year: 2012 end-page: 1255 article-title: Hepatocellular carcinoma publication-title: Lancet contributor: fullname: Bruix – volume: 5 start-page: 29 issue: 1 year: 1998 end-page: 34 article-title: Pattern and management of recurrent hepatocellular carcinoma after liver transplantation publication-title: J Hepatobiliary Pancreat Surg contributor: fullname: Valente – volume: 134 start-page: 1908 issue: 7 year: 2008 end-page: 1916 article-title: Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma publication-title: Gastroenterology contributor: fullname: Aoki – volume: 157 start-page: 463 issue: 3 year: 2015 end-page: 472 article-title: Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy publication-title: Surgery contributor: fullname: Inoue – ident: bibr20-1533033818801362 doi: 10.1148/radiology.214.3.r00mr02761 – ident: bibr54-1533033818801362 doi: 10.1002/cncr.21832 – ident: bibr55-1533033818801362 doi: 10.1016/j.jvir.2016.06.010 – ident: bibr29-1533033818801362 doi: 10.1002/cncr.10384 – ident: bibr9-1533033818801362 doi: 10.1097/00000658-199902000-00009 – ident: bibr4-1533033818801362 doi: 10.1053/jhep.2001.23561 – volume: 61 start-page: 1387 issue: 133 year: 2014 ident: bibr12-1533033818801362 publication-title: Hepatogastroenterology contributor: fullname: Yamagami T – ident: bibr47-1533033818801362 doi: 10.18632/oncotarget.8331 – ident: bibr8-1533033818801362 doi: 10.1097/01.sla.0000094549.11754.e6 – volume: 49 start-page: 249 issue: 43 year: 2002 ident: bibr7-1533033818801362 publication-title: Hepatogastroenterology contributor: fullname: Castroagudin JF – ident: bibr56-1533033818801362 doi: 10.1148/radiol.14141568 – ident: bibr5-1533033818801362 doi: 10.1002/hep.510300629 – ident: bibr57-1533033818801362 doi: 10.18632/oncotarget.11514 – ident: bibr14-1533033818801362 doi: 10.1002/cncr.30008 – ident: bibr59-1533033818801362 doi: 10.1016/j.surg.2014.10.019 – ident: bibr1-1533033818801362 doi: 10.1016/S0140-6736(11)61347-0 – ident: bibr37-1533033818801362 doi: 10.21873/anticanres.11211 – volume: 24 start-page: 219 issue: 4 year: 2018 ident: bibr21-1533033818801362 publication-title: Diagn Interv Radiol contributor: fullname: Zhang R – ident: bibr24-1533033818801362 doi: 10.1055/s-0030-1247133 – ident: bibr43-1533033818801362 doi: 10.1245/s10434-006-9220-8 – ident: bibr18-1533033818801362 doi: 10.1148/radiol.2343040350 – ident: bibr34-1533033818801362 doi: 10.1002/lt.21078 – ident: bibr35-1533033818801362 doi: 10.1002/hep.24199 – ident: bibr10-1533033818801362 doi: 10.1097/MEG.0000000000000383 – ident: bibr45-1533033818801362 doi: 10.1097/MEG.0b013e32834c5b13 – ident: bibr44-1533033818801362 doi: 10.1007/s00270-013-0708-x – ident: bibr3-1533033818801362 doi: 10.1053/j.gastro.2008.02.091 – ident: bibr33-1533033818801362 doi: 10.1245/s10434-016-5136-0 – ident: bibr53-1533033818801362 doi: 10.1002/cncr.21043 – ident: bibr30-1533033818801362 doi: 10.1007/s00432-016-2286-1 – ident: bibr28-1533033818801362 doi: 10.1002/hep.510280322 – ident: bibr32-1533033818801362 doi: 10.1016/j.jhep.2015.02.034 – ident: bibr27-1533033818801362 doi: 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E – ident: bibr15-1533033818801362 doi: 10.1016/S1470-2045(17)30683-6 – ident: bibr46-1533033818801362 doi: 10.1002/1097-0142(19921101)70:9<2263::AID-CNCR2820700909>3.0.CO;2-M – ident: bibr16-1533033818801362 doi: 10.1148/radiol.2281020718 – ident: bibr39-1533033818801362 doi: 10.1007/s12013-014-9840-8 – ident: bibr36-1533033818801362 doi: 10.1097/01.RVI.0000094601.83406.e1 – ident: bibr19-1533033818801362 doi: 10.1097/MD.0000000000002252 – volume: 59 start-page: 1560 issue: 117 year: 2012 ident: bibr49-1533033818801362 publication-title: Hepatogastroenterology contributor: fullname: Yang Y – ident: bibr25-1533033818801362 doi: 10.1055/s-2007-1007122 – ident: bibr17-1533033818801362 doi: 10.1002/cncr.20892 – ident: bibr31-1533033818801362 doi: 10.1001/jamasurg.2015.4257 – ident: bibr23-1533033818801362 doi: 10.1007/PL00009947 – ident: bibr13-1533033818801362 doi: 10.1016/j.jvir.2009.11.006 – ident: bibr48-1533033818801362 doi: 10.1016/j.surg.2005.02.008 – ident: bibr11-1533033818801362 doi: 10.1097/COC.0b013e3181967da0 – ident: bibr6-1533033818801362 doi: 10.1097/TP.0b013e3182a89383 – ident: bibr22-1533033818801362 doi: 10.1002/hep.510250116 – ident: bibr51-1533033818801362 doi: 10.1016/j.crad.2014.01.015 – ident: bibr2-1533033818801362 doi: 10.1056/NEJMra1001683 – ident: bibr41-1533033818801362 doi: 10.3109/02656736.2011.605099 – ident: bibr52-1533033818801362 doi: 10.1097/01.RVI.0000182185.47500.7A – ident: bibr58-1533033818801362 doi: 10.1097/SLA.0000000000000882 – ident: bibr50-1533033818801362 doi: 10.1111/hpb.12324 – ident: bibr42-1533033818801362 doi: 10.1016/j.ejso.2014.11.002 – ident: bibr38-1533033818801362 doi: 10.1007/s12328-015-0599-2 – ident: bibr26-1533033818801362 – ident: bibr40-1533033818801362 doi: 10.1159/000367755 |
SSID | ssj0026631 |
Score | 2.2439518 |
Snippet | Aim:
This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma... This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma... Aim: This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma... Aim:This study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma... AIMThis study aimed to evaluate the efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma... |
SourceID | pubmedcentral proquest crossref pubmed sage |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1533033818801362 |
SubjectTerms | Ablation Confidence intervals Embolization Hepatectomy Liver cancer Nomograms Original |
SummonAdditionalLinks | – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9RAEF5qC-KL-NvUKiOI4EO4JLv5cU9Sy5VD6HFUi30Lu9kNLXhJveYe-qf53_lNsnftWfQ1m5AhMzvzzc7kGyE-pNoCOMgsNG6chKrOk3DMI8McwkGOAJNXPYnrySybnqmv5-n5jpiu_4Xhtsq1T-wdtW0rPiMfAYcgdAJ_FyNt-BSg6kafr36FPD-K66x-mMYDsZfEigu2e18ms_npJvlCZPXcqTKMpLpTshzxNchXMDVZLLNkO0Tdw5332yfv9ID1Yen4iXjs8SQdDgbwVOy45pl4eOIr5s_F7wlzROjqhtqa5m5ZrYAGHdJ9goHAKeNRM7TDEVwD0mRn6cdld0F9EOsbPmGhNFmY9qf_ZZOAc-mUz-mZ2YmmCGhdywUA7milIx5O1LQLTYc8fnxY5tLA4oZ0Y0nTfNlydx8Eplm76NvDqGtxmYXu6NsK3gv2_0KcHU--H01DP64hrFSWdGFmkftZp1KppbPOZK6yhYmjwuVGpUbpPHaFM-O4jp1Uqq5TZQAWpck1krAkky_FbtM27rUg-BkXFRbY0iFdyxJT1eNK4nkZ6dhGLhCf1hoqrwZWjjL2xOV_azMQB2sVln5_Xpe31hSI95tl7Cz-WoMaSqTGSNeAd3HPq0Hjm5dJQBueIh-IfMsWNjcwa_f2SnN50bN3M8KG4wvER7aaW5H-Jf_-_-V_Ix4BwxXDqdCB2O2WK_cWOKkz7_wW-ANqXxIT priority: 102 providerName: ProQuest – databaseName: SAGE Open Access dbid: AFRWT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBbpBkovpe86TcsUSqEHN7YlP_ZUlrDLUkgIaUJyM5Ylk0Btl4192J-Wf9dv_NhmuxR6tWR70IxmvtGMZoT4FGYGwEFGrrbTwFVFHLhTbhlmYQ5iGJg474q4npxGy0v1_Tq83hPVeBdmWMG7r5xWBYo6Zc27m0-jj4Yg4xGDFHwx4WJiPlTwt7Yp0_60e2yqwU84PN2WHNnOOR9y7Y632x6J_YCL4k7E_mxxfnWxcdFgf4cKq9L1pHoQ2Nz557Yh20Gnu0mWDzLFOuO1eCaeDqiTZr2YPBd7tnohHp8McfWX4n7OlSSyfE11QWd2lbfAjLZu7whiBNWNV3WfNEdQIHCmraGr2-aGOlPXpYVCjmle6vrncLGTgIbpnE_zuf4TLWH2mprDBJz3Ssfcwqiqy4xm3KS8H-YAQrmmrDKU0dmq5hxAEEynddklkVFT4zET3dCPFjoOu-SVuFzML46X7tDUwc1VFDRuZOAhGqtCmUlrrI5sbhLte4mNtQq1ymLfJlZP_cK3UqmiCJUGpJQ6zuCqBZF8LSZVXdm3gqCNrJcYIFALpy4KdF5Mc4n3pZf5xrOO-DJyKP3V1-5I_aG8-d_cdMThyMJ0lMEU2BdwDV9OHPFxM4z9x6vVsyGFAw2nDqgYc970HN_8TAIAca95R8RbsrCZwLW9t0eq25uuxjfjcKhHR3xmqflD0r_oP_jfie_EE2C-pD9FOhSTZtXa98BVjf4wbIbfwasgEQ priority: 102 providerName: SAGE Publications |
Title | Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival |
URI | https://journals.sagepub.com/doi/full/10.1177/1533033818801362 https://www.ncbi.nlm.nih.gov/pubmed/30244651 https://www.proquest.com/docview/2313978628/abstract/ https://search.proquest.com/docview/2111746568 https://pubmed.ncbi.nlm.nih.gov/PMC6153531 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB6SFEIupe-oTc0USqEHxZZWLx9dY2MKNsZNiG9CK62IIZKCKx_y0_rv-u1KcuOGXnoSaPUYNLMz3-x-miH67CcZgIMIbKmGru3loWsPdcswhXAQIsCEqSniOl8Es2vv-9pfH5Hf_QtjSPup3FyWd8Vlubk13Mr7Iu13PLH-cj7WIAW20z-m41CILkVvsyyE0LZIqrAHwnu0N9nX5yBIpGuQOfDcZ3QqEKN0O_DDsPQEaz6lTD7ifZlQNH1Bz1sMyaNG1pd0pMpXdDpvd8lf06-JrguRpA9c5bxU23QHBKiQ4jOMAo4Yt8qGAsdwB0iNVcY3m_qWTeAyJE9YJU8KWd21v2kysC2v9Nq8rubEMwSxutKL_prFymPdkKisioRHuuV4M6y3A4oHTsqME15uK83og8C8qApDCeO6wmktdM0_dvBYsPk3dD2dXI1ndtuiwU69wK3tIEO-lynPF4lQmZKBSrNIOoNIhdLzpZeEjoqUHDq5o4Tn5bnvSQBEIcMEiZcbiLd0UlalOieGb1GDKAOeVEjRAlem-TAVuF8MEicbKIu-dhqK75tKHLHTFiv_W7EWXXQqjNs5-TMGkgX4wpMjiz7thzGb9Ndq1BAjHUaKBoyLa941Gt-_rDMVi8IDW9hfoCt1H47AgE3F7tZgLfqireaPSP-S__1_v-IDnQHSRc0i0QWd1Nud-gjYVMseJss67NGz0XR1c4Xjt8liueqZRYiemUK_AX8WGuQ |
link.rule.ids | 230,315,733,786,790,870,891,12083,21416,21994,27886,27957,27958,31754,31755,33779,33780,43345,43840,44980,45368,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9NAEF1BKgEXxGcxFBgkhMTBqu1df-SESpUqQBNFpRW9WV7vWq1E7JI6h_40_h1v7E3aUMHVa8sjz-zMe7PjGSHex4UBcJCJr-0w8lWVRv6QR4ZZhIMUASYtuyauk2kyPlFfT-NTl3C7dGWVK5_YOWrTlJwj3wUOQegE_s4-XfzyeWoUn666ERp3xZaSoCoDsfV5NJ0drSkX4qnrmCr9QKobB5W7fA1SZdyQLJRJtBmYbqHN20WTNyq_umB08Eg8dCiS9nq1PxZ3bP1E3Ju4c_Kn4veIO0MU5RU1Fc3solwCA1qQfIJZwBXjUd0XwREcAsixNfTjvD2jLnR1ZZ6wSxrNdfPT_ahJQLd0xNl57udEY4SxtuG0P9ex0j6PJKqbeUF7PHS8X-YDgfkVFbWhgmaLhmv6IDBNm3lXFEZtg8ssdEvfl_BZsPpn4uRgdLw_9t2QBr9USdT6iQHjM1bFspDWWJ3Y0mQ6DDKbahVrVaShzawehlVopVJVFSsNiCh1WoB6RYl8LgZ1U9sXguBdbJAZIEoLkpZEuqyGpcTzMihCE1hPfFxpKL_oe3HkoWtX_rc2PbGzUmHuduVlfm1Dnni3XsZ-4q_VqyEHIQZJA8rFPdu9xtcvkwA0PDveE-mGLaxv4F7dmyv1-VnXs5txNdydJz6w1VyL9C_5X_5f_rfi_vh4cpgffpl-eyUeAMVlfV5oRwzaxdK-BlJq9Ru3Hf4AZBwRRg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF6hVKq4IN4YCgwSQuJgans3fhyjkig8GkWlVXuzvN61Wqmxq-Ac-tP4d3xjb0JDhMQ1u96MPLMz3-yOvxHi_bAwAA4y9rXNIl9VSeRn3DLMIhwkCDBJ2ZG4Hs_i6Zn6ejG8cLU5_C2Me4M_P3FZFSTqnDXv7htTHbo7xkPGKFgwZS6xsPPAe0plaTAQe6PJyfnpJuNCOHWEqdIPpLpzT7mzxnZc2gGbuzWTdwq_ulg0eSgeOBBJo17rj8Q9Wz8W-8fumvyJ-DVmYoiivKWmorldlitAQIscn2AV8MR4VPc1cAR_gNzYGjq_ai-pi1xdlSfMksYL3Vy77zQJ4JZO-HCe6ZxoiijWNnzqz2WsdMQdiepmUdCIe473w3wfsLilojZU0HzZcEkfBKZZs-hqwqht8DML3dKPFVwWjP6pOJuMT4-mvuvR4Jcqjlo_Nkj4jFVDWUhrrI5taVIdBqlNtBpqVSShTa3Owiq0UqmqGioNhCh1UiDzimL5TAzqprYvBMG52CA1AJQWOVoc6bLKSonnZVCEJrCe-LjWUH7TU3HkoWMr_1ubnjhYqzBfm1QOKAv0hZVTT7zbDGM78dvq1ZAjH0aOBpCLOc97jW_-TALPcOt4TyRbtrCZwFTd2yP11WVH2c2wGt7OEx_Yav6I9C_5X_7vxLdif_55kn__Mvv2StwHmkv786EDMWiXK_saiKnVb9y--A39iQ6L |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Percutaneous+Thermal+Ablation+Combined+With+Transarterial+Embolization+for+Recurrent+Hepatocellular+Carcinoma+After+Hepatectomy+and+a+Prognostic+Nomogram+to+Predict+Survival&rft.jtitle=Technology+in+cancer+research+%26+treatment&rft.au=Yuan%2C+Zhuhui&rft.au=Wang%2C+Yang&rft.au=Hu%2C+Caixia&rft.au=Gao%2C+Wenfeng&rft.date=2018-01-01&rft.issn=1533-0346&rft.eissn=1533-0338&rft.volume=17&rft_id=info:doi/10.1177%2F1533033818801362&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_1533033818801362 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1533-0346&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1533-0346&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1533-0346&client=summon |